Shares of Charles River Laboratories International, Inc. (NYSE:CRL) have received an average recommendation of “Buy” from the eleven ratings firms that are currently covering the stock, Marketbeat.com reports. Five research analysts have rated the stock with a hold recommendation, four have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $97.28.

A number of research firms have commented on CRL. Robert W. Baird reiterated a “buy” rating and set a $114.00 target price on shares of Charles River Laboratories International in a research report on Friday, September 1st. Jefferies Group LLC reiterated a “buy” rating and set a $120.00 target price on shares of Charles River Laboratories International in a research report on Tuesday. BidaskClub upgraded Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, August 22nd. Zacks Investment Research downgraded Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Tuesday, July 25th. Finally, Citigroup Inc. reiterated a “neutral” rating and set a $104.00 target price (up from $91.00) on shares of Charles River Laboratories International in a research report on Wednesday, June 28th.

In other news, insider Davide Molho sold 10,948 shares of the company’s stock in a transaction on Thursday, June 22nd. The stock was sold at an average price of $100.00, for a total value of $1,094,800.00. Following the sale, the insider now directly owns 27,497 shares in the company, valued at $2,749,700. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider David Ross Smith sold 2,552 shares of the company’s stock in a transaction on Monday, August 14th. The shares were sold at an average price of $67.10, for a total value of $171,239.20. Following the completion of the sale, the insider now owns 11,671 shares in the company, valued at $783,124.10. The disclosure for this sale can be found here. Insiders sold 79,982 shares of company stock worth $7,951,868 over the last 90 days. Company insiders own 2.20% of the company’s stock.

Several large investors have recently modified their holdings of the company. Alps Advisors Inc. lifted its position in shares of Charles River Laboratories International by 0.3% in the second quarter. Alps Advisors Inc. now owns 5,350 shares of the medical research company’s stock valued at $541,000 after acquiring an additional 14 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its position in shares of Charles River Laboratories International by 0.5% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 6,953 shares of the medical research company’s stock valued at $703,000 after acquiring an additional 33 shares in the last quarter. Bbva Compass Bancshares Inc. lifted its position in shares of Charles River Laboratories International by 0.8% in the second quarter. Bbva Compass Bancshares Inc. now owns 6,004 shares of the medical research company’s stock valued at $607,000 after acquiring an additional 50 shares in the last quarter. World Asset Management Inc lifted its position in shares of Charles River Laboratories International by 2.2% in the second quarter. World Asset Management Inc now owns 2,762 shares of the medical research company’s stock valued at $279,000 after acquiring an additional 59 shares in the last quarter. Finally, M&T Bank Corp lifted its position in shares of Charles River Laboratories International by 1.8% in the second quarter. M&T Bank Corp now owns 4,358 shares of the medical research company’s stock valued at $441,000 after acquiring an additional 76 shares in the last quarter. Institutional investors and hedge funds own 95.82% of the company’s stock.

Charles River Laboratories International (NYSE CRL) traded down 0.27% on Friday, reaching $106.02. The company had a trading volume of 572,862 shares. The company’s 50-day moving average is $103.01 and its 200-day moving average is $95.28. The company has a market capitalization of $5.05 billion, a PE ratio of 27.94 and a beta of 0.99. Charles River Laboratories International has a 52-week low of $67.20 and a 52-week high of $109.59.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, August 9th. The medical research company reported $1.29 EPS for the quarter, topping the Zacks’ consensus estimate of $1.22 by $0.07. The company had revenue of $469.13 million for the quarter, compared to the consensus estimate of $458.25 million. Charles River Laboratories International had a return on equity of 27.02% and a net margin of 10.13%. Charles River Laboratories International’s quarterly revenue was up 8.1% compared to the same quarter last year. During the same period in the previous year, the business earned $1.20 earnings per share. Equities analysts anticipate that Charles River Laboratories International will post $5.10 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This story was originally published by American Banking News and is owned by of American Banking News. If you are viewing this story on another domain, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/09/16/charles-river-laboratories-international-inc-crl-receives-consensus-recommendation-of-buy-from-analysts.html.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Analyst Recommendations for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.